The present invention relates to compounds and compositions for use in a method of treating and/or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and/or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.

The present invention relates to a condensation product obtainable by reaction of a1) at least one aromatic system or heteroaromatic system, a2) at least one carbonyl compound, a3) if appropriate at least one sulfonating agent, and a4) if appropriate at least one urea derivative, where the condensation product has a molecular weight Mw of at least 300 g/mol, for use in a method for the treatment of COVID-19. The invention further relates to a use of the condensation product in a therapeutic method for the treatment of COVID-19; to a use of the condensation product as disinfectant against the virus SARS-CoV-2; and to a use of the condensation product for the production of a medicament which is an antiviral agent against SARS-CoV-2.

The invention relates to a solid deep eutectic solvent (solid DES) that is solid at 20° C., comprising a salt of an active pharmaceutical ingredient, the method to obtain the solid deep eutectic solvent and the use of the deep eutectic solvent for medical treatment. The solid deep eutectic solvent is obtained by at least partially removing a plasticizer from a first DES.

The invention relates to a solid deep eutectic solvent (solid DES) that is solid at 20° C., comprising a salt of an active pharmaceutical ingredient, the method to obtain the solid deep eutectic solvent and the use of the deep eutectic solvent for medical treatment. The solid deep eutectic solvent is obtained by at least partially removing a plasticizer from a first DES.

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one LINE 1 (L-1) endonuclease inhibitor.

The present invention patent application relates essentially to an additive, the function of which is to enhance immunity, prevent various diseases and increase detoxification of the organism. The additive is composed of: 60 mcg of vitamin A; 4.5 mg of vitamin C; 1 mg of vitamin E; 3.4 mcg of selenium; 0.5 mg of copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyme Q10; 5 mg of pycnogenol; 0.13 mg of vitamin B2; 1.6 mg of vitamin B3; 0.13 mg of vitamin B6; 24 mcg of folic acid; 0.24 mcg of vitamin B12; 2 mg of glutathione; 100 mg of leucine; 20 mg of isoleucine; 20 mg of valine; 50 mg of glycine; 50 mg of taurine; 300 mg of glutamine; 60 mg of acetylcysteine; 50 mg of cysteine; 100 mg of methionine; 0.5 mg of vitamin B5; 2 mg of lycopene; and 4 mg of resveratrol.

The present invention patent application relates essentially to an additive, the function of which is to enhance immunity, prevent various diseases and increase detoxification of the organism. The additive is composed of: 60 mcg of vitamin A; 4.5 mg of vitamin C; 1 mg of vitamin E; 3.4 mcg of selenium; 0.5 mg of copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyme Q10; 5 mg of pycnogenol; 0.13 mg of vitamin B2; 1.6 mg of vitamin B3; 0.13 mg of vitamin B6; 24 mcg of folic acid; 0.24 mcg of vitamin B12; 2 mg of glutathione; 100 mg of leucine; 20 mg of isoleucine; 20 mg of valine; 50 mg of glycine; 50 mg of taurine; 300 mg of glutamine; 60 mg of acetylcysteine; 50 mg of cysteine; 100 mg of methionine; 0.5 mg of vitamin B5; 2 mg of lycopene; and 4 mg of resveratrol.

The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.

The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.

Mucolytic agents for use in treating pulmonary sarcoidosis are described herein. Patients in need of treatment for pulmonary sarcoidosis are administered a therapeutically effective amount of a mucolytic agent such as DNase I, Mesna or DiMesna. In some embodiments, the DNase I is a recombinant human DNase I such as dornase alfa.